NJ S2143 | 2022-2023 | Regular Session

Note: Carry Over of previous S1650
Note: Carry Over of previous A2830

Status

Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on March 7 2022 - 25% progression, died in committee
Action: 2022-03-07 - Introduced in the Senate, Referred to Senate Commerce Committee
Pending: Senate Commerce Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

Sponsors


History

DateChamberAction
2022-03-07SenateIntroduced in the Senate, Referred to Senate Commerce Committee

Same As/Similar To

A2544 (Same As) 2022-02-14 - Introduced, Referred to Assembly Financial Institutions and Insurance Committee
S1650 (Carry Over) 2020-02-13 - Introduced in the Senate, Referred to Senate Commerce Committee
A2830 (Carry Over) 2020-02-20 - Introduced, Referred to Assembly Financial Institutions and Insurance Committee

Subjects


New Jersey State Sources


Bill Comments

feedback